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An effective approach in the treatment of benzodiazepine (BZD) overdosing and
detoxification is flumazenil (FLU). Studies in chronic users who discontinued BZD in
a clinical setting suggested that multiple slow bolus infusions of FLU reduce BZD
withdrawal symptoms. The aim of this study was to confirm FLU efficacy for reducing
BZD withdrawal syndrome by means of continuous elastomeric infusion, correlated to
drugs plasma level and patients’ compliance.
Methods: Seven-day FLU 1 mg/day subcutaneously injected through an elastomeric
pump and BZDs lormetazepam, clonazepam, and lorazepam were assessed by
HPLC-MS/MS in serum of patients before and after 4 and 7 days of FLU continuous
infusion treatment. Changes in withdrawal severity were assessed by using the BZD
Withdrawal Scale (BWS).
Results: Fourteen patients (mean age ± SD 42.5 ± 8.0 years, 5 male and 9 female),
admitted to the hospital for high-dose BZD detoxification, were enrolled in the study.
Serum FLU concentrations significantly decreased from 0.54 ± 0.33 ng/ml (mean ± SD)
after 4 days of treatment to 0.1 ± 0.2 ng/ml at the end of infusion. Lormetazepam
concentrations were 502.5 ± 610.0 ng/ml at hospital admission, 26.2 ± 26.8 ng/ml after
4 days, and 0 at the end of treatment. BWS values decreased during FLU treatment
temporal period. FLU was well-tolerated by patients.
Conclusions: Elastomeric FLU infusion for BZD detoxification is a feasible
administration device to maintain adequate, constant, and tolerated FLU concentrations
for reducing BZD withdrawal symptoms.
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INTRODUCTION
Although benzodiazepines (BZDs) constitute one of the most broadly prescribed drug classes
worldwide, the frequent and often inappropriate use is a problem that remains considerably
underestimated by practitioners and most regulatory agencies (1). BZD can produce tolerance
and dependence; thus, their use is recommended for a limited time (2). Surveys carried out in
the 1990s in France, Germany, Italy, and the United Kingdom showed that 3.9% of hypnotic
drug users and 3.2% of anxiolytic drug users had been taking a dose exceeding the recommended
Benini et al. High Dose of Benzodiazepine Detoxification
one (2–4). In Italy, about 7.5–10% of adult population are BDZ
users, half of these being long-term users (LTU) with a diagnosis
of BZD use disorder (5). Another study conducted in Italy
showed that 14.0% of patients visiting general practitioners were
taking BZDs, with 4.7% of the total sample being LTU, using
BZDs daily for at least 12 months (6).
BZD tolerance was first reported in 1961 (7), but this
phenomenon has been often obscured by the enthusiastic use
of these drugs, which were able to replace barbiturates. The low
toxicity coupled to a high potential of tolerance can lead to
very high-dose misuse (8). From a clinical point of view, the
only proposed solution of a gradual reduction of BZD is too
simplistic. For long-term users, in general, if properly applied,
gradually reducing the dosage works, but it is much less effective
for high-dose users (2, 8, 9). This is worth mentioning because
withdrawing from high doses of BZD carries significant risk for
the health of the patient (2, 10).
It is in this area of HDUs that the use of flumazenil
(FLU), used worldwide to treat the overdose of BZD, has been
demonstrated as effective (9, 11–13). Experimental findings have
shown that FLU acts as a BZDpartial agonist with a weak intrinsic
activity, when administered by slow intravenous infusion. While
withdrawal symptoms may be brought on by the use of FLU,
BZD-tolerant patients only reported mild symptoms (14, 15).
BZDs positively modulate γ-aminobutyric acid (GABA)
through distinct binding sites on GABAA receptors, and there is
little variation among BZDs in pharmacodynamical factors such
as selectivity and efficacy. Consequently, the choice of a particular
BZD for clinical use is primarily based on pharmacokinetic
features. Only one drug, flumazenil (FLU), is currently approved
to reverse the effects of BZDs. FLU is a BZD partial agonist
commonly used in the treatment of BZD overdose. Studies
in chronic users who have discontinued BZDs suggested that
multiple slow bolus infusions of FLU reduce the symptoms of
BZD withdrawal when compared to placebo (9). The mechanism
of FLU action remains, however, unclear: its action may
facilitate the coupling of GABAA and BZD receptor complexes,
presumably by reversing the down-regulation/uncoupling that
occurs with long-term BZD use (16). This mechanism is
supposed to underlie FLU’s weak agonist action and may explain
its ability to attenuate BZD withdrawal symptoms (9). FLU does
not antagonize the effects of other CNS sedative-hypnotics, such
as ethanol, opioids, or general anesthetics (17).
FLU owns a rapid and extensive distribution phase with high
volume of distribution and a second phase with fast metabolic
elimination and short half-life (18). Its brief BZD-antagonism
duration is due to a rapid hepatic elimination, determining its
short half-life (60–90min) and high plasma clearance (31–78
l/h). The low plasma protein binding of FLU (about 50%) does
not limit its wide distribution (apparent distribution volume
0.6–1.6 l/kg) or its partly flow-dependent hepatic elimination
(19, 20). Pharmacokinetic parameters of FLU do not change
whether the drug is administered alone or in combination with
other BZDs (18). For BZD detoxification, a viable method is
the intravenous administration of FLU by using multiple bolus
infusions either alone (14, 21) or in combination with tapering
doses of BZDs (11).
The pharmacodynamical mechanisms of FLU are therefore
crucial to determine its clinical effect, which could be achieved
thanks to specific FLU infusion parameters in order to guarantee
timing and extent of receptor occupancy (14). Thus, the
choice of the most appropriate mode of delivery must be
based on the correlation between FLU infusion parameters,
plasma levels, and clinical endpoint. Our addiction unit has
been employing FLU for high-dose BZD detoxifications since
2003, initially by means of endovenous continuous infusion
administered by day. Such mode of delivery was both inconstant
at maintaining adequate serum levels, being unfeasible for the
night, and uncomfortable for the patient. In order to maintain
constant serum concentration of FLU and to reduce modality of
administration from multiple to single, we aimed to deliver FLU
by slow subcutaneous infusion by using an elastomeric infusion
pump at constant flow. In this study, we correlated the efficacy
of continuous elastomeric FLU infusion on BZD withdrawal
clinical endpoint to both drugs’ (FLU and BZDs) plasma levels
and, of equal importance, to patients’ compliance and tolerance
to treatment.
MATERIALS AND METHODS
This study was approved by the Ethical Review Board of
the University Hospital (protocol number: 50771; prog. n.
683CESC). Informed consent was obtained from each subject.
Subjects
Five male and nine female patients (mean age ± SD 42.5 ±
8.0 years), admitted to the hospital for BZD detoxification, were
enrolled in the study (see Table 1 for patients’ characteristics).
The BZD use was stopped on day 1 of admission. The therapy
with antidepressants, if any (Table 1), was maintained and
continued after discharge.
All patients reported a history of BZD dependence according
to the Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition (DSM-5) criteria (22). Before hospitalization, all
patients were interviewed by a physician to assess degree of
BZD dependence and general health conditions. All patients had
voluntarily contacted the Addiction Unit of Verona University
Hospital and were aware of their BZD dependence.
Inclusion criteria were as follows: (i) age older than 18 years;
(ii) diagnosis of BZD use disorder according to the DSM-5
criteria; (iii) BZD abuse lasting more than 6 months; and (iv)
high dose of BZD abuse, meaning BZD intake exceeding at
least five times the recommended daily amount (e.g., >50mg in
diazepam equivalents). Individuals were excluded if presenting
the following: (i) current substance use disorder, defined as a
history of illicit drug dependence or abuse within the previous
6 months; (ii) active medical illnesses or psychosis; and (iii)
previous history of seizures, but not due to BZD withdrawal.
Elastomeric Pump
Patients were treated with a solution containing 7mg of
flumazenil (Anexate R©, Roche), available commercially in 0.5
mg/5ml vials at pH = 4. The elastomeric pump (Infusor LV 1.5,
code 2C1087K, Baxter S.p.A., Rome, Italy) was arranged with a
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1 M 38 LRZ 25 mg/day Agomelatine
CLO 2 mg/day
2 M 44 LRM 75 mg/day None
3 F 42 LRM 75 mg/day Duloxetine
4 F 55 ALP 35 mg/day Escitalopram
5 F 47 CLO 12 mg/day Mirtazapine











7 F 47 LRM 400 mg/day Agomelatine
DLZ 12 mg/day
8 F 37 LRM 40 mg/day Agomelatine
9 M 36 LRM 150 mg/day None
10 F 43 LRZ 50 mg/day Citalopram
11 F 31 LRM 100 mg/day Paroxetine
12 F 30 LRM 75 mg/day Sertraline
13 M 38 ALP 15 mg/day Escitalopram
14 M 32 LRM 150 mg/day Citalopram
ALP, aprazolam; CLO, clonazepam; DLZ, delorazepam; DZP, diazepam; F, female; FLZ,
flurazepam; LRM, lormetazepam; LRZ, lorazepam; M, male; TRZ, triazolam.
maximum capacity of 250ml and constant release of 1.5 ml/h
for 7 days. The pump was connected to the patient’s anterior
abdominal wall via a butterfly needle inserted subcutaneously.
The pump, releasing 1mg of flumazenil every 24 h, was then
placed in a small bag that could be carried attached to the belt
or on the shoulder. Patients’ tolerance for the infusion device
was investigated on a daily basis, through clinical examination
and interview.
Throughout the detoxification, FLU subcutaneous infusion
(FLU-SI) was associated with therapeutic doses of clonazepam,
orally administered every day in the evening and gradually
tapered from 6mg on the 1st day to 0.5–2.0mg on the last day
of treatment. The different speed in the tapering of clonazepam
was due to clinical criteria, in particular we considered the quality
of sleep and the intensity of withdrawal symptoms. In this way, at
the end of hospitalization, 3/14 patients were discharged with no
clonazepam, and 11/14 (78.6%) patients were discharged with a
low dose of clonazepam ranging from 0.5 to 2.0 mg/day; these
patients were recommended to gradually taper it in a few weeks
(8). Unfortunately, patients were not followed-up as outpatients,
and we cannot be sure whether they succeeded in tapering and
eventually stopping clonazepam.
Ten days prior to the admission, anti-epileptic prophylaxis (1
g/day valproic acid or levetiracetam) was given to all patients
in order to prevent seizures during treatment. Anti-epileptic
treatment wasmaintained during the hospital stay and for further
20–40 days after discharge.
Patients under concurrent treatment with antidepressant
(12/14 patients, see Table 1) were maintained under
this pharmacotherapy.
Sampling Protocol
Blood samples were collected without anticoagulant at the
moment of admission, after 4 days of FLU treatment, and at
the end of the 7 days of treatment, before discharge from the
addiction unit.
Samples were centrifuged (3,000 rpm, 10min) and sera were
frozen at−80◦C until HPLC-MS analysis.
Flumazenil and Main BZD Concentration
Analysis
Blank serum samples, used for the development and validation of
the procedure, were obtained from healthy volunteers abstinent
from any drug during the week before sampling. A 250-µl aliquot
of serum was added to an equal volume of 0.1M phosphate
solution (pH 8.8), and the mixture was spiked with the IS
(diazepam-D5) to have a final concentration of 40 ng/ml. The
mixtures were added with 1.5ml of ethyl acetate, then extracted
by vortex-mixing for 1min, and centrifuged at 4,000 rpm for
15min. The organic phase was then evaporated to dryness
under nitrogen stream and the residue dissolved in 50 µl of
ultrapure water.
The determination of FLU and lormetazepam was obtained
by using a model 1290 UHPLC coupled to a model 6450
triple quadruple mass spectrometer (Agilent Technologies,
Waldbronn, Germany) operating in positive ionization mode.
Gradient elution was performed on a UHPLC ZORBAX
Eclipse reversed-phase column (RRHD 2.1mm × 100mm,
1.8µm) (Agilent) by mixing 5mM aqueous ammonium formate
containing 0.01% formic acid (eluent A) and acetonitrile added
with 0.01% formic acid at a flow rate of 0.5 ml/min (eluent
B) from 10 to 95% B in 7min. The analyses were performed
in multiple reaction ion monitoring (MRM) mode using the
following ion transitions: FLU 304 217, 232, and 258 (collision
energy: 20 eV); lormetazepam 335 317, 289, and 177.0 (collision
energy: 20 eV); and diazepam-D5 290 262 (collision energy:
27 eV).
Method was linear in the concentration range of 78–5,000
pg/ml for FLU and of 3–200 ng/ml for lormetazepam. Lower limit
of quantification (LLOQ) corresponded to 78 pg/ml for FLU and
3 ng/ml for lormetazepam.
Precision (% CV) of the assay was ≤9.8% for both the
analytes, whereas the inter-assay accuracy was ≤3.8 and ≤4.7%,
respectively. The accuracy and CVs for day-to-day tests resulted
always below 7.93%.
Withdrawal Assessment
A Benzodiazepine Withdrawal Scale (BWS) form exploring
withdrawal symptoms (33 items each with a score of 0–4 from
best to worst) was given to each patient for daily report (23).
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Statistical Analysis
Statistical analysis was performed using the software Graph
Pad PRISM version 6.0. The results were expressed as mean ±
standard error of the mean (SEM). Student’s t-test was utilized
for statistical analysis by comparing different treatment times of
the same group of patients.
RESULTS
Drug plasma levels are shown in Figure 1. Plasma FLU
concentrations were 0.54 ± 0.089 ng/ml (mean ± SEM) at T1
after 4 days of continuous subcutaneous infusion, ranging from
0.14 to 1.4 ng/ml. Values recorded at T2 (end of therapy) were
0.09 ± 0.05 ng/ml, with FLU concentrations below limits of
detection in 10 patients out of 14.
Lormetazepam (LRM) levels were 502.5 ± 163.0 ng/ml at T0
baseline. A significant decrease (11.2 ± 5.7 ng/ml; p = 0.008) in
LRM levels was recorded at T1 and 0.43± 0.43 ng/ml at T2. High
LRM plasma levels recorded at T0 are in agreement with patients’
self-report of BZD use at admission, whereas low T1 and T2 levels
confirmed compliance to detoxification treatment.
Lorazepam (LRZ) levels showed a similar pattern, with
high initial plasma concentrations (83.1 ± 27.4 ng/ml), then a
significant decrease to 20.4 ± 11.4 ng/ml (p = 0.01) at T1 and
9.4± 5.6 ng/ml at T2 after 7 days of FLU administration.
Clonazepam (CLN) plasma levels were low at T0 (14.0 ±
8.6 ng/ml), 35.5 ± 5.0 ng/ml at T1, and 25.4 ± 3.9 ng/ml at T2.
Note that three patients were treated with CLN before hospital
admission (see Table 1).
According to different BZD behaviors, BWS showed a
decrease from 26.4 to 17.7 points, as portrayed in Figure 2.
During the treatment, 10/14 subjects (71.4%) completed the
Benzodiazepine Withdrawal Scale (BWS) with scores ranging
from 0 to 132 on a daily basis, in order to subjectively assess
their withdrawal symptoms. Four out of 14 patients could not
complete the BWS. As shown in Figure 2, BWS improved
significantly during FLU treatment in all subjects. Nomajor event
(i.e., convulsive crisis) occurred.
The elastomeric pump was well tolerated by patients. Since
FLU is further diluted in a saline solution inside the device,
no skin irritation around the insertion of the needle was
noticed. Since elastomeric pumps are light and compact, patients
appreciated the freedom ofmovement and rated them as painless,
safe, and comfortable, with no bound to the pump and respecting
the privacy about the therapy, whereas nurses acknowledged they
required less time to manage them.
DISCUSSION
BZD represents a class of drugs characterized by low acute
toxicity even at high doses in the absence of any concurrent
drug abuse such as alcohol and opioids (2). Literature data
on the toxicity of high-dose BZD are old and mostly based
on anecdotal case reports. The lack of clinical studies and the
high tolerability of these drugs have produced the erroneous
perception that the administration of high doses of BZD for
a prolonged time, although not recommended, could be not
harmful. However, several complications have been associated
to chronic BZD consumption, such as memory and attention
deficit, inability to learn, increased risk of falls, road accidents,
depression, and reduced quality of life (Lugoboni DAD 2014).
Thus, although the prolonged use of high dose of BZD seems not
to induce liver toxicity, it remains a serious health concern (24).
The severe discomfort experienced by patients stopping long-
term BZD use led to the development of treatment strategies
for discontinuing these medications (1, 10). The common
management of BZD withdrawal syndrome includes, either
individually or in combination: (i) a gradual tapering of the
drug; (ii) switching to an equivalent dose of a long half-life BZD
before tapering withdrawal (10, 25); and (iii) adding medications
prior to detoxification and continuing those medications after
BZD discontinuation (1, 10). A potential approach is the abrupt
discontinuation of themedication and a rapid BZDdetoxification
using FLU. FLU is commonly used in the treatment of BZD
overdose; it is usually considered a BZD antagonist (9). When
compared to placebo, bolus infusion of flumazenil (1mg in
5min) produced effects similar to BZD withdrawal in BZD users
(23, 26). Nonetheless, results of studies in chronic BZD users
who have discontinued BZD use suggest that multiple slow
bolus infusions of flumazenil reduce the symptoms of withdrawal
(9, 11, 21, 27).
Subcutaneous route of FLU administration was previously
described only in three patients (14), suggesting the usefulness of
this route for its excellent tolerability, efficacy, and improvement
on measure of psychological distress. According to these data,
we decided to administer FLU by subcutaneous route utilizing
elastomeric pumps normally used for pain control in cancer
patients or, more recently, for continuous infusion of antibiotics
(28) or for treatment of idiopathic hypersomnia (29).
To our knowledge, the results present in this paper are the
first data of FLU serum concentrations following subcutaneous
infusion by elastomeric pump described in literature. FLU serum
concentrations were low, but consistent with data of FLU
administered by i.v. route (14).
FLU is characterized by short half-life (0.8–1.2 h) (30) and
requires repeated doses or continuous infusion to reverse BZD
overdose. In spite of its low lipophilicity, FLU has a large volume
of distribution, and its weak binding to plasma proteins explains
its rapid distribution. Moreover, FLU is extensively metabolized
by hepatic cytochromes P450 3A4, 3A5, and 2C9 and readily
eliminated. Maximum brain concentrations are reached 5 to
8min after i.v. administration (31).
Subcutaneous administration of flumazenil eliminates some
problems with first-pass hepatic metabolism observed orally
and is likely to facilitate better absorption. Subcutaneous
administration also provides continuous dosing, which would be
hard to achieve with oral or sublingual administration, and the
slow absorption may abrogate side effects related to high serum
concentrations. The subcutaneous route is easier to establish
than the intravenous administration, and there is no risk for
patient’s veins. Study data suggested that flumazenil administered
by the s.c. route might have equitable clinical benefits to i.v.
administration, but it might be superior in that it requires less
Frontiers in Psychiatry | www.frontiersin.org 4 March 2021 | Volume 12 | Article 646038
Benini et al. High Dose of Benzodiazepine Detoxification
FIGURE 1 | Drugs plasma levels. Individual plasma levels (ng/ml; ordinates) for flumazenil, lormetazepam, clonazepam, and lorazepam at different time-points
(abscissa), i.e., at admission (T0), four (T1) and seven days after flumazenil start of elastomeric infusion.
FIGURE 2 | Withdrawal Symptom Scores from day 1 to day 7 of FLU-SI treatment.
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clinical monitoring and is likely associated with less equipment
problems (i.e., dislodged or blocked i.v. needle/line) and adverse
events (i.e., venous tissue irritation). These advantages, as well as
an improved patient mobility over the treatment period, will also
likely result in increased patient satisfaction (9, 14).
The subcutaneous route of administration may be associated
to the absence of adverse events associated with i.v. FLU
administration. In fact, our patients did not report any kind of
adverse events such as those frequently reported during or after
FLU administration (8, 14, 32).
Our results demonstrated low and constant serum
concentrations during all treatment and a prompt decrease
nearly to 0 at the end of treatment, protecting patients from peak
serum levels. We utilized an elastomeric infusion pump mostly
utilized in our hospital for analgesic purposes.
Several elastomeric pumps are commercially available, and
they are calibrated in different conditions, including operating
temperature and pressure, viscosity of fluid, backpressure, and
time recommended between filling of the device and beginning
of the infusion. All of these factors affect the infusion rate of
pumps. Elastomeric infusion pumps are feasible to use and less
bed bounding for patients, although a little less precise than
other pumps.
Moreover, Höjer et al. (33) studied the stability of infusion
solutions of flumazenil in concentrations of 1.0 and 5.0µg/ml
stored for periods of up to 9 months and concluded that the
stability of flumazenil in infusion solution was satisfactory.
Importantly, serum levels of other BZDs (such as LRM and
LRZ) are 0 after 4 days of FLU administration, proving both the
efficacy of FLU and patients’ compliance despite the elevated BZD
plasma levels measured at the beginning of the treatment. The
good patients’ compliance was confirmed by CLN concentrations
in serum that showed a trend to decrease after 7 days. Most
interestingly, during the detoxification process, all patients
reported low levels of craving for BZD, which might represent
a rarely seen feature in the spectrum of drug detoxification.
According to previous studies, high-dose BZD chronic use
determines a severe impairment of psychological, physical, and
social functioning, along with a significant reduction of quality of
life (34, 35).
The main limitation to this study is the lack of a follow-up
phase to determine whether all patients were successfully able
to taper and suspend clonazepam and to assess the relapse rate.
Another limitation of the study is its monocentric design. The
problem is not new. Although more than 30 years have passed
since the first studies of the efficacy of FLU in the treatment
of addiction to high doses of BZD, to our knowledge, there are
no more than five centers worldwide offering this treatment.
This continues to represent a major obstacle to the definition
of more shared and standardized protocols. Currently, FLU
protocol is the same for all patients, regardless of sex, age, BMI,
and BZD daily intake. Future prospects should include further
investigations of the individual variables and clinical outcomes in
order to individualize the detoxification therapy.
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